Suppr超能文献

开发并验证一种易于使用的风险评分系统,用于筛查 HBV 相关代偿性慢性肝脏疾病高危静脉曲张患者。

Development and Validation of an Easy-to-Use Risk Scoring System for Screening High-Risk Varices in Patients with HBV-Related Compensated Advanced Chronic Liver Disease.

机构信息

Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, People's Republic of China.

Sichuan University-University of Oxford Huaxi Joint for Gastrointestinal Cancer Centre, No. 2222 Xin Chuan, Chengdu, Sichuan, People's Republic of China.

出版信息

Dig Dis Sci. 2021 Dec;66(12):4518-4524. doi: 10.1007/s10620-020-06764-8. Epub 2021 Jan 12.

Abstract

BACKGROUND

A large portion of patients with compensated advanced chronic liver disease (cACLD) do not have varices or only have low risk varices.

AIMS

To create and validate an easy-to-use risk scoring system to identify high-risk varices (HRV) and spare esophagogastroduodenoscopy (EGD) in patients with hepatitis B virus (HBV)-related cACLD.

METHODS

In total, 334 patients with HBV-related cACLD who had undergone routine laboratory tests and ultrasound examination were enrolled. Multivariate logistic regression analysis was used to determine which variables were the independent risk factors for the presence of HRV, so as to establish the scoring system for screening HRV. The criteria were tested in a training cohort with 221 patients and validated in a validation cohort with 113 patients.

RESULTS

In the training cohort, the prevalence of HRV was 29.5%. Albumin (ALB) [OR 0.83; 95% confidence index (CI) 0.77-0.90; P < 0.0001], platelet count (PLT) (OR 0.96, 95% CI 0.96-0.99; P < 0.0001) and portal vein diameter (OR 1.40; 95% CI 1.15-1.71; P = 0.001) were independent risk factors for the presence of HRV. The negative predictive value was > 95%, when albumin-platelet-portal vein diameter varices scores (APP score) were < 0.24. One hundred twenty-five of 221 (56.6%) patients met an APP score < 0.24 with a 4.8% HRV miss rate. In the validation cohort, 59 of 113 (51.3%) patients met the APP score < 0.24 with a 1.7% HRV miss rate.

CONCLUSIONS

APP score is a potential model for safely screening HRV and sparing EGDs in patients with HBV-related cACLD.

摘要

背景

很大一部分代偿期慢性肝病(cACLD)患者没有静脉曲张或只有低危静脉曲张。

目的

建立并验证一种易于使用的风险评分系统,以识别乙型肝炎病毒(HBV)相关 cACLD 患者的高危静脉曲张(HRV)并避免进行食管胃十二指肠镜检查(EGD)。

方法

共纳入 334 例接受常规实验室检查和超声检查的 HBV 相关 cACLD 患者。多变量逻辑回归分析用于确定哪些变量是 HRV 存在的独立危险因素,从而建立筛查 HRV 的评分系统。在 221 例患者的训练队列中测试标准,并在 113 例患者的验证队列中验证。

结果

在训练队列中,HRV 的患病率为 29.5%。白蛋白(ALB)[比值比(OR)0.83;95%置信区间(CI)0.77-0.90;P<0.0001]、血小板计数(PLT)(OR 0.96,95%CI 0.96-0.99;P<0.0001)和门静脉直径(OR 1.40;95%CI 1.15-1.71;P=0.001)是 HRV 存在的独立危险因素。当白蛋白-血小板-门静脉直径静脉曲张评分(APP 评分)<0.24 时,阴性预测值>95%。221 例患者中 125 例(56.6%)APP 评分<0.24,静脉曲张漏诊率为 4.8%。在验证队列中,113 例患者中有 59 例(51.3%)APP 评分<0.24,静脉曲张漏诊率为 1.7%。

结论

APP 评分是一种安全筛查 HBV 相关 cACLD 患者 HRV 并避免 EGD 的潜在模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbf4/8589772/d9f9908d5400/10620_2020_6764_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验